Provided by Tiger Fintech (Singapore) Pte. Ltd.

Tiziana Life Sciences PLC

1.57
+0.09006.08%
Post-market: 1.620.0500+3.18%18:46 EDT
Volume:377.22K
Turnover:589.16K
Market Cap:163.28M
PE:-11.77
High:1.60
Open:1.56
Low:1.50
Close:1.48
Loading ...

Company Profile

Company Name:
Tiziana Life Sciences PLC
Exchange:
NASDAQ
Establishment Date:
1998
Employees:
9
Office Location:
14/15 Conduit Street,London,Greater London,United Kingdom
Zip Code:
W1S 2XJ
Phone:
- -
Fax:
- -
Introduction:
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

Directors

Name
Position
Gabriele Marco Antonio Cerrone
Executive Chairman
Kunwar Shailubhai
Chief Executive Officer, Chief Scientific Officer and Executive Director
Gregor MacRae
Non-Executive Director
Vaseem A. Palejwala
Director, Clinical operations
Willy Simon
Non-Executive Director

Shareholders

Name
Position
Kunwar Shailubhai
Chief Executive Officer, Chief Scientific Officer and Executive Director
Tiziano Lazzaretti
Chief Financial Officer
Jules S. Jacob
Senior Director, CMC & Non-Clinical Development